Latest From Eternygen GmbH
Biscayne and Japanese CRO SNBL create spin-outs to advance programs; liver disease specialist Ascletis gains funds as it shifts away from HCV; Neon gets $100m to put into its cancer vaccines; and other highlights of recent VC funding.
Venture capital investment fell $2.1bn to $7.79bn in 2016, but it was still the second-best year of VC funding for biopharma firms since 2006. Also, Venrock and Correlation closed new health care and technology funds and 10 companies raised $126.8m.
Germany’s Evotec hopes to evolve into an integrated multi-service biopharma company through its three-pronged business strategy comprising a high-growth drug-discovery business, a series of pipeline options that pose no financial obligation for the biotech, and a growing list of scientific collaborations that offer potential long-term value.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April through May 2014.
- Therapeutic Areas
- Metabolic Disorders
- Western Europe
- Parent & Subsidiaries
- Eternygen GmbH
- Senior Management
Marco Janezic, CEO
Grit Zahn, PhD, Head, Rsch.
- Contact Info
Phone: 30 1207 6983
c/o Bayer CoLaborator (Gebäude S141)
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.